(2S,4R,5S,6S)-2-[({[(2S,3R,4R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]-5-acetamido-4-hydroxy-6-[(1S,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid

• ChemBase编号: 2219
• 分子式: C20H31N4O16P
• 平均质量: 614.451101
• 单一同位素质量: 614.14726756
• SMILES: CC(=O)N[C@H]1[C@H](O)C[C@](O[C@@H]1[C@@H](O)[C@H](O)CO)(O[P@@](=O)(O)OC[C@@H]1O[C@H]([C@H](O)[C@H]1O)n1ccc(N)nc1=O)C(=O)O
• Canonical SMILES: OC[C@H]([C@@H]([C@H]1O[C@@](C[C@H]([C@@H]1NC(=O)C)O)(O[P@](=O)(OC[C@@H]1O[C@H]([C@@H]([C@H]1O)O)n1ccc(nc1=O)N)O)C(=O)O)O)O
• InChI: InChI=1S/C20H31N4O16P/c1-7(26)22-12-8(27)4-20(18(32)33,39-16(12)13(29)9(28)5-25)40-41(35,36)37-6-10-14(30)15(31)17(38-10)24-3-2-11(21)23-19(24)34/h2-3,8-10,12-17,25,27-31H,4-6H2,1H3,(H,22,26)(H,32,33)(H,35,36)(H2,21,23,34)/t8-,9-,10+,12+,13+,14+,15-,16+,17-,20+/m1/s1
• InChIKey: TXCIAUNLDRJGJZ-XPVTVWDUSA-N

名称和登记号

名称

• IUPAC标准名: (2S,4R,5S,6S)-2-[({[(2S,3R,4R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]-5-acetamido-4-hydroxy-6-[(1S,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
• IUPAC传统名: (2S,4R,5S,6S)-2-({[(2S,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy(hydroxy)phosphoryl}oxy)-5-acetamido-4-hydroxy-6-[(1S,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
• 别名: Cytidine-5'-Monophosphate-5-N-Acetylneuraminic Acid

登记号

• PubChem SID: 160965672; 46504831
• PubChem CID: 46936403

理论计算性质

JChem

• Acid pKa: 1.5311238
• 质子受体: 16
• 质子供体: 10
• LogD (pH = 5.5): -10.469976
• LogD (pH = 7.4): -11.445853
• Log P: -5.8631806
• 摩尔折射率: 125.4201 cm^3
• 极化性: 51.143093 Å^3
• 极化表面积: 320.69 Å^2
• 可自由旋转的化学键: 11
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: -2.7
• LOG S: -1.23
• 溶解度: 3.63e+01 g/l

详细说明

DrugBank - DB02485

• Drug Groups: experimental
• Description: A nucleoside monophosphate sugar which donates N-acetylneuraminic acid to the terminal sugar of a ganglioside or glycoprotein. [PubChem]